DocDollars

Ultragenyx Pharmaceutical Inc.

CA · United States · Reporting entity ID 100000196876

Total reported 2019–2025
$73.2M
#128 of 2,960 reporting companies — 0.1% of all reported industry payments
$3.73M in general payments across 30,345 records, plus $69.4M in research funding across 8,657 records.

How it breaks down

General payments $3,729,718
Research funding $69,442,924

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Ultragenyx Pharmaceutical Inc. reported $73.2M to US doctors and teaching hospitals from 2019 to 2025, ranking #128 of 2,960 reporting companies. 95% of that was research funding and 5% general payments such as consulting, speaking, food and travel. 30,345 general payment records and 8,657 research records were filed.

Common questions about Ultragenyx Pharmaceutical Inc.

How much has Ultragenyx Pharmaceutical Inc. paid US doctors?

Ultragenyx Pharmaceutical Inc. reported $73,172,642 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $3,729,718 in general payments, $69,442,924 in research funding.

How does Ultragenyx Pharmaceutical Inc. rank among drug and device companies?

It ranks #128 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Ultragenyx Pharmaceutical Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.